Verona Pharma Plc ADR (NASDAQ: VRNA)’s stock price has increased by 0.61 compared to its previous closing price of 67.50. However, the company has seen a 6.92% increase in its stock price over the last five trading sessions. seekingalpha.com reported 2025-02-27 that Verona Pharma plc (NASDAQ:VRNA ) Q4 2024 Earnings Conference Call February 27, 2024 9:00 AM ET Company Participants David Zaccardelli – President and CEO Mark Hahn – CFO Christopher Martin – CCO Conference Call Participants Andrew Tsai – Jefferies Yasmeen Rahimi – Piper Sandler Tiago Fauth – Wells Fargo Tom Shrader – BTIG Ram Selvaraju – HCW Joon Lee – Truist Boobalan Pachaiyappan – ROTH Operator Good morning ladies and gentlemen. Welcome to the Verona Pharma Fourth Quarter and Full Year 2024 Financial Results and Conference Call.
Is It Worth Investing in Verona Pharma Plc ADR (NASDAQ: VRNA) Right Now?
VRNA has 36-month beta value of 0.12. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VRNA is 72.66M, and currently, short sellers hold a 10.71% ratio of that float. The average trading volume of VRNA on March 05, 2025 was 1.34M shares.
VRNA’s Market Performance
VRNA stock saw an increase of 6.92% in the past week, with a monthly gain of 15.15% and a quarterly increase of 71.37%. The volatility ratio for the week is 6.37%, and the volatility levels for the last 30 days are 5.19% for Verona Pharma Plc ADR (VRNA). The simple moving average for the last 20 days is 6.15% for VRNA stock, with a simple moving average of 99.56% for the last 200 days.
Analysts’ Opinion of VRNA
Many brokerage firms have already submitted their reports for VRNA stocks, with ROTH MKM repeating the rating for VRNA by listing it as a “Buy.” The predicted price for VRNA in the upcoming period, according to ROTH MKM is $68 based on the research report published on January 10, 2025 of the current year 2025.
Wells Fargo, on the other hand, stated in their research note that they expect to see VRNA reach a price target of $50. The rating they have provided for VRNA stocks is “Overweight” according to the report published on October 03rd, 2024.
Jefferies gave a rating of “Buy” to VRNA, setting the target price at $38 in the report published on May 22nd of the previous year.
VRNA Trading at 22.00% from the 50-Day Moving Average
After a stumble in the market that brought VRNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.53% of loss for the given period.
Volatility was left at 5.19%, however, over the last 30 days, the volatility rate increased by 6.37%, as shares surge +12.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +68.80% upper at present.
During the last 5 trading sessions, VRNA rose by +6.45%, which changed the moving average for the period of 200-days by +384.73% in comparison to the 20-day moving average, which settled at $63.96. In addition, Verona Pharma Plc ADR saw 46.24% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRNA starting from ZACCARDELLI DAVID, who sale 640,264 shares at the price of $5.01 back on Dec 05 ’24. After this action, ZACCARDELLI DAVID now owns 14,367,552 shares of Verona Pharma Plc ADR, valued at $3,205,226 using the latest closing price.
ZACCARDELLI DAVID, the President and CEO of Verona Pharma Plc ADR, sale 162,800 shares at $5.01 during a trade that took place back on Dec 06 ’24, which means that ZACCARDELLI DAVID is holding 14,204,752 shares at $815,400 based on the most recent closing price.
Stock Fundamentals for VRNA
Current profitability levels for the company are sitting at:
- -3.66 for the present operating margin
- 0.93 for the gross margin
The net margin for Verona Pharma Plc ADR stands at -4.1. The total capital return value is set at -0.36. Equity return is now at value -76.51, with -44.38 for asset returns.
Based on Verona Pharma Plc ADR (VRNA), the company’s capital structure generated 0.37 points at debt to capital in total, while cash flow to debt ratio is standing at -1.0. The debt to equity ratio resting at 0.6. The interest coverage ratio of the stock is -6.57.
Currently, EBITDA for the company is -138.53 million with net debt to EBITDA at 2.2. When we switch over and look at the enterprise to sales, we see a ratio of 10.44. The receivables turnover for the company is 1.13for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.63.
Conclusion
To put it simply, Verona Pharma Plc ADR (VRNA) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
